Haematology: multiple myeloma.
作者信息
Firth John
出版信息
Clin Med (Lond). 2019 Jan;19(1):58-60. doi: 10.7861/clinmedicine.19-1-58.
Abstract
摘要
相似文献
1
Haematology: multiple myeloma.血液学：多发性骨髓瘤。
Clin Med (Lond). 2019 Jan;19(1):58-60. doi: 10.7861/clinmedicine.19-1-58.
2
Significance of bone marrow biopsy in the multiple myeloma.骨髓活检在多发性骨髓瘤中的意义。
Bibl Haematol. 1978;45:81-6. doi: 10.1159/000402187.
3
[Multiple myeloma].[多发性骨髓瘤]
Dtsch Med Wochenschr. 2012 Mar;137 Suppl 1:S14-7. doi: 10.1055/s-0032-1301853. Epub 2012 Mar 21.
4
Extramedullary myeloma relapses.髓外骨髓瘤复发。
Ann Hematol. 2012 Sep;91(9):1511-2. doi: 10.1007/s00277-012-1432-3. Epub 2012 Feb 25.
5
Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents.客座编辑评论：了解新型药物时代多发性骨髓瘤的发病机制及不断演变的治疗模式。
Int J Hematol. 2011 Oct;94(4):307-309. doi: 10.1007/s12185-011-0950-4. Epub 2011 Oct 13.
6
Plasmablastic multiple myeloma with Dutcher bodies.伴有达彻小体的浆母细胞性多发性骨髓瘤。
Indian J Pathol Microbiol. 2008 Jul-Sep;51(3):442-3. doi: 10.4103/0377-4929.42557.
7
Relapse of multiple myeloma: diagnosis by clot section alone with negative bone marrow aspirate and trephine biopsy.多发性骨髓瘤复发：仅通过凝块切片诊断，骨髓穿刺和活检均为阴性。
Indian J Pathol Microbiol. 2009 Apr-Jun;52(2):290-1. doi: 10.4103/0377-4929.48957.
8
Nephroquiz 5: a 51-year-old man with kidney failure.肾脏病例问答5：一名51岁的肾衰竭男性。
Iran J Kidney Dis. 2010 Oct;4(4):340-4.
9
Detection of malignant plasma cells in the bone marrow and peripheral blood of patients with multiple myeloma.多发性骨髓瘤患者骨髓和外周血中恶性浆细胞的检测
Methods Mol Biol. 2002;179:85-91. doi: 10.1385/1-59259-238-4:085.
10
Plasma cell myeloma with histiocyte-like morphology.具有组织细胞样形态的浆细胞骨髓瘤。
Int J Hematol. 2017 Sep;106(3):307-309. doi: 10.1007/s12185-017-2249-6. Epub 2017 May 29.
引用本文的文献
1
Immunophenotypic characteristics and prognostic value of peripheral blood circulating plasma cells in patients with newly diagnosed multiple myeloma.新诊断多发性骨髓瘤患者外周血循环浆细胞的免疫表型特征及预后价值
J Med Biochem. 2025 Jun 13;44(3):668-677. doi: 10.5937/jomb0-55319.
2
Regulatory role of the METTL3/MALAT1 axis in multiple myeloma progression.METTL3/MALAT1轴在多发性骨髓瘤进展中的调控作用。
J Bone Oncol. 2025 Jun 12;53:100695. doi: 10.1016/j.jbo.2025.100695. eCollection 2025 Aug.
3
Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation.多发性骨髓瘤预后及免疫微环境评估中与外泌体相关基因特征的综合分析
Cancer Immunol Immunother. 2025 Jul 15;74(8):269. doi: 10.1007/s00262-025-04097-x.
4
Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states.单细胞蛋白质组学分析揭示了多发性骨髓瘤的异质性以及肿瘤免疫微环境在前体和晚期状态下的动态变化。
Neoplasia. 2025 Aug;66:101189. doi: 10.1016/j.neo.2025.101189. Epub 2025 Jun 6.
5
Global trends and collaborations in bortezomib-induced neurotoxicity research: a bibliometric analysis (2002-2024).硼替佐米诱导的神经毒性研究的全球趋势与合作：一项文献计量分析（2002 - 2024年）
Front Pharmacol. 2025 May 14;16:1584383. doi: 10.3389/fphar.2025.1584383. eCollection 2025.
6
Investigating additional malignancy rates and prognostic factors in multiple myeloma patients: a Surveillance, Epidemiology, and End Results (SEER) database retrospective cohort study.探究多发性骨髓瘤患者的额外恶性肿瘤发生率及预后因素：一项监测、流行病学与最终结果（SEER）数据库回顾性队列研究。
Transl Cancer Res. 2025 Apr 30;14(4):2192-2206. doi: 10.21037/tcr-24-1721. Epub 2025 Apr 14.
7
Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trials.isatuximab单药治疗复发或难治性多发性骨髓瘤的疗效和安全性：临床试验的汇总分析
Ann Hematol. 2025 Apr;104(4):2337-2350. doi: 10.1007/s00277-025-06343-9. Epub 2025 Apr 21.
8
Relationship of Plasma Cell Infiltration Rates with F-FDG PET/CT Data and Hematological Parameters in Multiple Myeloma.多发性骨髓瘤中浆细胞浸润率与F-FDG PET/CT数据及血液学参数的关系
Mol Imaging Radionucl Ther. 2025 Feb 7;34(1):26-30. doi: 10.4274/mirt.galenos.2024.78557.
9
The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review.抗体药物偶联物贝兰他单抗莫福汀治疗多发性骨髓瘤的综合综述
Blood Lymphat Cancer. 2024 Dec 6;14:71-87. doi: 10.2147/BLCTT.S490021. eCollection 2024.
10
Common laboratory results-based artificial intelligence analysis achieves accurate classification of plasma cell dyscrasias.基于常见实验室结果的人工智能分析可实现浆细胞异常增生疾病的准确分类。
PeerJ. 2024 Nov 4;12:e18391. doi: 10.7717/peerj.18391. eCollection 2024.
Zotero 插件